icon-folder.gif   Conference Reports for NATAP  
 
  HepDART 2011
December 4, 2011 - December 8, 2011
Kauai, HI, USA
Back grey_arrow_rt.gif
 
 
 
Characterization of Virologic Resistance in HCV Genotype 1 Null Responders Receiving a Dual Direct- Acting Antiviral Combination of NS3 Protease Inhibitor Asunaprevir (ASV; BMS-650032) and NS5A Replication Complex Inhibitor Daclatasvir (DCV; BMS-790052) (oral presentation)
 
 
  Reported by Jules Levin
HepDART 2011
Koloa, Hawaii, December 4-8, 2011
 
F McPhee, D Hernandez, F Yu, J Ueland, R Fridell, C Wang, A Monikowski, N Zhou, S Levine, D Gardiner, E Hughes, H Watanabe, H Ishikawa, H Kumada, M Gao

hepDart1.gif

hepDart2.gif

hepDart3.gif

hepDart4.gif

hepDart5.gif